Etanercept

Overview

Etanercept, sold under the brand name Enbrel among others, is a biologic medical product that is used to treat autoimmune diseases by interfering with tumor necrosis factor (TNF), a soluble inflammatory cytokine, by acting as a TNF inhibitor. It has US Food and Drug Administration (FDA) approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF.[1] WP

Etanercept is a fusion protein produced by recombinant DNA. It fuses the TNF receptor to the constant end of the IgG1 antibody. First, the developers isolated the DNA sequence that codes the human gene for soluble TNF receptor 2, which is a receptor that binds to tumor necrosis factor. Second, they isolated the DNA sequence that codes the human gene for the Fc end of immunoglobulin G1 (IgG1). Third, they linked the DNA for TNF receptor 2 to the DNA for IgG1 Fc. Finally, they expressed the linked DNA to produce a protein that links the protein for TNF receptor 2 to the protein for IgG1 Fc.[2] WP

The prototypic fusion protein was first synthesized and shown to be highly active and unusually stable as a modality for blockade of TNF in vivo in the early 1990s by Bruce A. Beutler, an academic researcher then at the University of Texas Southwestern Medical Center at Dallas, and his colleagues.[3][4] WP

These investigators also patented the protein, selling all rights to its use to Immunex, a Seattle biotechnology company that was acquired by Amgen in 2002.[5][6] WP

It is a large molecule, with a molecular weight of 150 kDa, that binds to TNFα and decreases its role in disorders involving excess inflammation in humans and other animals, including autoimmune diseases such as ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and, potentially, in a variety of other disorders mediated by excess TNFα. Etanercept is a therapeutic alternative on the World Health Organization's List of Essential Medicines.[7][8] WP

Uses, dosage and effects

Medical uses

In the United States, etanercept is indicated for: WP

• Moderate to severe rheumatoid arthritis (RA) (November 1998)[9][10] WP
• Moderate to severe polyarticular juvenile rheumatoid arthritis (May 1999)[9][11] WP
• Psoriatic arthritis (January 2002)[9][12] WP
• Ankylosing spondylitis (AS) (July 2003)[9][13][14] WP
• Moderate to severe plaque psoriasis (April 2004)[9][15] WP

In the European Union, etanercept is indicated to treat: WP

• moderate to severe active rheumatoid arthritis[16] WP
• severe, active and progressive rheumatoid arthritis[16] WP
• juvenile idiopathic arthritis[16] WP
• polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents[16] WP
• active and progressive psoriatic arthritis[16] WP
• enthesitis-related arthritis WP
• axial spondyloarthritis[16] WP
• severe active ankylosing spondylitis[16] WP
• severe non-radiographic axial spondyloarthritis[16] WP
• moderate to severe plaque psoriasis[16] WP
• chronic severe plaque psoriasis pediatric plaque psoriasis[16] WP

Unrecognized uses

An American physician, Edward Tobinick, has attempted to use etanercept to treat chronic neurological dysfunction after stroke and brain injury and issued US and foreign patents. Writing for Science-Based Medicine, Steven Novella said that it was "unethical for physicians to practice outside of their area of competence and expertise". Tobinick sued Novella in response, and lost. Of this treatment, the American Academy of Neurology advise "there is insufficient evidence to determine its effectiveness and that the treatment may be associated with adverse outcomes and high cost".[17–20] WP

Risks and side effects

Adverse effects

On 2 May 2008, the US Food and Drug Administration (FDA) placed a black box warning on etanercept due to a number of serious infections associated with the drug. Serious infections and sepsis, including fatalities, have been reported with the use of etanercept including reactivation of latent tuberculosis and hepatitis B infections.[9][21][22] WP

Injection site reactions such as redness and pain are common, occurring in approximately 11.4% of cases.[23] WP

Pharmacology

Mechanism of action

Etanercept reduces the effect of naturally present TNF, and hence is a TNF inhibitor, functioning as a decoy receptor that binds to TNF.[24] WP

Tumor necrosis factor (TNF) is a cytokine produced by lymphocytes and macrophages, two types of white blood cells. It mediates the immune response by attracting additional white blood cells to sites of inflammation and through additional molecular mechanisms that initiate and amplify inflammation. Inhibition of its action by etanercept reduces the inflammatory response, which is especially useful for treating autoimmune diseases. WP

There are two types of TNF receptors: those found embedded in white blood cells that respond to TNF by releasing other cytokines, and soluble TNF receptors that are used to deactivate TNF and blunt the immune response. In addition, TNF receptors are found on the surface of virtually all nucleated cells (red blood cells, which are not nucleated, do not contain TNF receptors on their surface). Etanercept mimics the inhibitory effects of naturally occurring soluble TNF receptors, the difference being that etanercept, because it is a fusion protein rather than a simple TNF receptor, has a greatly extended half-life in the bloodstream, and therefore a more profound and long-lasting biologic effect than a naturally occurring soluble TNF receptor.[25] WP

History

History

The first etanercept-related patent was filed by Immunex in September 1989. The fusion protein was developed by Bruce A. Beutler, an academic researcher then at the University of Texas Southwestern Medical Center at Dallas, and colleagues, who patented it and licensed the rights in 1995 to Immunex. Another patent on such fusion protein technology from Brian Seed at Massachusetts General Hospital was licensed to Immmunex in 1997.[26][27][28] WP

Etanercept was approved for use in the United States in November 1998.[9][29] WP

Etanercept was approved for use in the European Union in February 2000.[16] WP

Legal status

Economics

The US retail price of etanercept has risen over time. In 2008, the cost of etanercept was $1,500 per month or $18,000 per year. By 2011, the cost had exceeded $20,000 per year. In 2013, a survey by the International Federation of Health Plans (IFHP) found that the average US cost for etanercept was $2,225 per month, or $26,700 per year. The IFHP report also found wide variation in prices charged to various US health plans, between $1,946 per month at the 25th percentile and $4,006 per month at the 95th percentile.[30–33] WP

Etanercept is more expensive in the US than in other countries. As of 2013, average monthly costs in surveyed nations ranged from $1,017 in Switzerland to $1,646 in Canada, compared to an average monthly cost of $2,225 per month in the US.[33] WP

Amgen sells etanercept within the US and Canada, while Pfizer, Inc. sells the drug outside of the US and Canada. Sales within the US and Canada were $3.5 billion in 2010. Sales of etanercept outside the US and Canada were $3.3 billion in 2010.[31][34] WP

In late March 2025, Amgen lost a lawsuit against Colorado over a prescription drug affordability board.[35] WP

Patents

The patent on etanercept was set to expire in October 2012, but, in the United States, a second patent, granting exclusivity for another 16 years, has been granted.[36][37] WP

Before the extension it seemed unlikely that a generic would have been available. As a biologic, etanercept is subject to different laws from those applicable to chemical formulations. Many countries do not permit the manufacture of generic biologics. However, the European Union and the United States (Biologics Price Competition and Innovation Act of 2009) do have in place a system to approve generic biologics (biosimilars) which "requires mandatory clinical testing and periodic review".[38] WP

In April 2013, the Indian pharma major Cipla made an announcement about launching the first biosimilar of Etanercept in India under the brand name Etacept for the treatment of rheumatic disorders.[39] WP

Biosimilars

In January 2016, Benepali was approved for use in the European Union.[40] WP

In February 2017, Lifmior was approved for use in the European Union. It was withdrawn from the market in February 2020.[41][42] WP

In June 2017, Erelzi was approved for use in the European Union.[43] WP

In March 2019, YLB113 (Etanercept biosimilar by YL Biologics) was approved in Japan.[44] WP

In April 2019, Eticovo received FDA approval.[45][46] WP

In May 2020, Nepexto was approved for use in the European Union.[47] WP

Rymti and Etera were approved for medical use in Australia in October 2020.[48–51] WP

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine. October 2003. doi:10.1038/nm939 · PMID 14520364
2. Journal / agency Drugs@FDA: FDA-Approved Drugs
3. Journal / agency Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. The Journal of Experimental Medicine. December 1991. doi:10.1084/jem.174.6.1483 · PMID 1660525 · PMC2119031
4. Journal / agency Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B. Expression of a TNF inhibitor in transgenic mice. Journal of Immunology. November 1993. doi:10.4049/jimmunol.151.10.5699 · PMID 7693816
5. Other U.S. Patent number: 5,447,851
6. Other Arthritis Drug Effective for Depression in Psoriasis Sufferers
7. Journal / agency Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology. June 2007. doi:10.1093/rheumatology/kem069 · PMID 17389658
8. Other The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. 2025
9. Journal / agency Enbrel- etanercept solution Enbrel- etanercept kit
10. Journal / agency Siegel YP. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088659.pdf. 2 November 1998
11. Journal / agency Weiss KD. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088844.pdf. 27 May 1999
12. Journal / agency Weiss KD. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/etanimm011502L.htm. 15 January 2002
13. Journal / agency Keegan P. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103795-5123_Enbrel_approv.pdf. 24 July 2003
14. Journal / agency Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA. TNF-alpha inhibitors for ankylosing spondylitis. The Cochrane Database of Systematic Reviews. April 2015. doi:10.1002/14651858.CD005468.pub2 · PMID 25887212 · PMC11200207
15. Journal / agency Walton M. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/biologics/2004/103795_5149ltr.pdf. 30 April 2004
16. Journal / agency Enbrel EPAR. 11 September 2009
17. Journal / agency New hope for survivors of stroke and traumatic brain injury. 31 October 2012
18. Other Methods for treatment of brain injury utilizing biologics
19. Other Another Free Speech Win In Libel Lawsuit Disguised As A Trademark Complaint. 24 February 2017
20. Other Practice Advisory: Etanercept for Poststroke Disability. 6 June 2016
21. Other Wyeth and Amgen heighten warning of life-threatening infections on skin drug Enbrel
22. Journal / agency Safety Update on TNF- α Antagonists: Infliximab and Etanercept
23. Journal / agency Kim PJ, Lansang RP, Vender R. A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections. Journal of Cutaneous Medicine and Surgery. July 2023. doi:10.1177/12034754231188444 · PMID 37533141 · PMC10486173
24. Journal / agency Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, Eivazi A, Kung J, Nguyen DH, Doberstein SK, Erard F, Ryffel B, Szymkowski DE. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. Journal of Immunology. August 2007. doi:10.4049/jimmunol.179.3.1872 · PMID 17641054
25. Journal / agency Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. Journal of Clinical Oncology. September 2005. doi:10.1200/JCO.2005.04.127 · PMID 16135466
26. Journal / agency Norman P. Enbrel and etanercept biosimilars: a tale of two patent systems. Pharmaceutical Patent Analyst. January 2017. doi:10.4155/ppa-2016-0043 · PMID 28201948
27. Other Gardner J. A three-decade monopoly: How Amgen built a patent thicket around its top-selling drug. 1 November 2021
28. Other Kowalczyk L. Lucrative Licensing Deals With Drug, Biotech Firms Are Raising Ethics Issues For Hospitals. 24 March 2002
29. Journal / agency Etanercept Product Approval Information - Licensing Action 12/2/98. 1 April 2016
30. Other What's behind the whopping price tags on the newest generation of drugs: The story behind the production of Enbrel, Amgen's popular rheumatoid arthritis drug, provides insights as to why bioengineered drugs are so expensive." Carol M. Ostrom, Seattle Times, 18 August 2008
31. Other Pollock A. Amgen's New Enbrel Patent May Undercut Health Care Plan. 23 November 2011
32. Other Co-pay hike a painful reality; Miracle drug monthly cost jumps from $42 to $600", Margery Eagan, Boston Herald, 3 November 2011. link 2
33. Other 2013 Comparative Price Report
34. Other Portions of the 2010 Financial Report
35. Other Amgen loses battle with Colorado over prescription drug affordability board. 2025-03-29
36. Other Patent Terms Extended Under 35 USC §156
37. Other New Amgen Enbrel patent could block biosimilars until 2028. 25 November 2011
38. Wikipedia Kaldre I. The Future of Generic Biologics: Should the United States "Follow-On" the European Pathway?. 2008
39. Other Cipla - Home
40. Journal / agency Benepali EPAR. 28 January 2016
41. Journal / agency Lifmior EPAR. 13 March 2017
42. Journal / agency Public statement on Lifmior: Withdrawal of the marketing authorisation in the European Union
43. Journal / agency Erelzi EPAR. 29 June 2017
44. Other Japanese approval for Lupin's etanercept biosimilar
45. Journal / agency Drug Approval Package: Eticovo. 18 June 2019
46. Other FDA approves etanercept biosimilar Eticovo
47. Journal / agency Nepexto EPAR. 24 March 2020
48. Other Australian Public Assessment Report for Etanercept. Feb 2021
49. Other AusPAR: Etanercept. 25 February 2021
50. Other Rymti ARTG
51. Other Etera ARTG

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.